Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

HEK-293 Cells IgG1 Isotype Control

IsoC IgG1 unconjugated
Catalog No. ABIN2181271

Quick Overview for HEK-293 Cells IgG1 Isotype Control (ABIN2181271)

Target

IgG1

Application

Isotype Control (IsoC)

Isotype

IgG1
  • Biological Activity

    Active

    Reactivity

    Human

    Host

    • 199
    • 40
    • 28
    • 6
    • 3
    • 2
    • 1
    • 1
    HEK-293 Cells

    Characteristics

    This protein carries no "tag". The protein has a calculated MW of 26 kDa. The protein migrates as 35 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

    Purity

    >95 % as determined by SDS-PAGE.

    Sterility

    0.22 μm filtered

    Endotoxin Level

    Less than 1.0 EU per μg by the LAL method.
  • Application Notes

    Optimal working dilution should be determined by the investigator.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

    Buffer

    50 mM Tris, 100 mM Glycine, pH 7.5

    Handling Advice

    Avoid repeated freeze-thaw cycles.

    Storage

    -20 °C

    Storage Comment

    Store at -20°C in lyophilized state after receipt. For long term storage, upon reconstitution rhIgG1 Fc should be aliquot and store at -20°C or -80°C.
  • Buecheler, Winzer, Tonillo, Weber, Gieseler: "Impact of Payload Hydrophobicity on the Stability of Antibody-Drug Conjugates." in: Molecular pharmaceutics, Vol. 15, Issue 7, pp. 2656-2664, (2019) (PubMed).

    Tao, Zhang, Meraner, Tovaglieri, Wu, Gerhard, Zhang, Stallcup, Miao, He, Hurdle, Breault, Brass, Dong: "Frizzled proteins are colonic epithelial receptors for C. difficile toxin B." in: Nature, Vol. 538, Issue 7625, pp. 350-355, (2017) (PubMed).

    Zhou, Wang, Tong, Okamoto, Shen, Zaro: "Single chain Fc-dimer-human growth hormone fusion protein for improved drug delivery." in: Biomaterials, Vol. 117, pp. 24-31, (2017) (PubMed).

    West, Pan, Tonsing-Carter, Hernandez, Pierce, Styke, Bowie, Garcia, Kocherginsky, Conzen: "GR and ER Coactivation Alters the Expression of Differentiation Genes and Associates with Improved ER+ Breast Cancer Outcome." in: Molecular cancer research : MCR, Vol. 14, Issue 8, pp. 707-19, (2017) (PubMed).

    Grenga, Kwilas, Donahue, Farsaci, Hodge: "Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack." in: Journal for immunotherapy of cancer, Vol. 3, pp. 52, (2015) (PubMed).

  • Target

    IgG1

    Target Type

    Antibody

    Background

    Crystallizable fragments composed of the carboxy-terminal halves of both IMMUNOGLOBULIN HEAVY CHAINS linked to each other by disulfide bonds. Fc fragments contain the carboxy-terminal parts of the heavy chain constant regions that are responsible for the effector functions of an immunoglobulin (COMPLEMENT fixation, binding to the cell membrane via FC RECEPTORS, and placental transport). IgG1 Fc was reported has a novel role as a potential anti-inflammatory drug for treatment of human autoimmune diseases.

    Molecular Weight

    26 kDa
You are here:
Chat with us!